BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 9768668)

  • 1. Secretory mechanisms of growth hormone (GH)-releasing peptide-, GH-releasing hormone-, and thyrotropin-releasing hormone-induced GH release in patients with acromegaly.
    Hanew K; Utsumi A; Tanaka A; Ikeda H; Yokogoshi Y
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3578-83. PubMed ID: 9768668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide.
    Renner U; Brockmeier S; Strasburger CJ; Lange M; Schopohl J; Müller OA; von Werder K; Stalla GK
    J Clin Endocrinol Metab; 1994 May; 78(5):1090-6. PubMed ID: 8175966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced GH responses to combined administration of GHRP and GHRH in patients with acromegaly.
    Hanew K; Utsumi A; Sugawara A; Shimizu Y; Abe K
    J Clin Endocrinol Metab; 1994 Mar; 78(3):509-12. PubMed ID: 8126120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The growth hormone (GH) response to GH-releasing peptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2), GH-releasing hormone, and thyrotropin-releasing hormone in acromegaly.
    Alster DK; Bowers CY; Jaffe CA; Ho PJ; Barkan AL
    J Clin Endocrinol Metab; 1993 Sep; 77(3):842-5. PubMed ID: 8370708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2) in rat anterior pituitary cells.
    Akman MS; Girard M; O'Brien LF; Ho AK; Chik CL
    Endocrinology; 1993 Mar; 132(3):1286-91. PubMed ID: 8095015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of growth hormone-releasing peptide-2 (GHRP-2) and GH-releasing hormone (GHRH) on the the cAMP levels and GH release from cultured acromegalic tumours.
    Chen C; Pullar M; Loneragan K; Zhang J; Clarke IJ
    J Neuroendocrinol; 1998 Jun; 10(6):473-80. PubMed ID: 9688350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
    Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
    J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
    Catalina PF; Mallo F; Andrade MA; García-Mayor RV; Diéguez C
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3663-7. PubMed ID: 9768681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture.
    Ishibashi M; Yamaji T
    J Clin Endocrinol Metab; 1985 May; 60(5):985-93. PubMed ID: 2858494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6.
    Popovic V; Damjanovic S; Micic D; Petakov M; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1994 Aug; 79(2):456-60. PubMed ID: 8045963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level.
    Popovic V; Damjanovic S; Micic D; Djurovic M; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Mar; 80(3):942-7. PubMed ID: 7883854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the actions of the growth hormone-releasing hexapeptide, GHRP.
    Bowers CY; Sartor AO; Reynolds GA; Badger TM
    Endocrinology; 1991 Apr; 128(4):2027-35. PubMed ID: 2004615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone release induced by growth hormone-releasing hexapeptide is not mediated by thyrotropin-releasing hormone in neonatal rats.
    Kacsóh B; Kacsóh G; Guzzardo MB; Black AC; Bisat T
    Pediatr Res; 1997 Feb; 41(2):249-57. PubMed ID: 9029647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.
    Villas-Boas Weffort RF; Ramos-Dias JC; Chipoch C; Lengyel AM
    Metabolism; 1997 Jun; 46(6):706-10. PubMed ID: 9186309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of selected endogenous peptides in growth hormone-releasing hexapeptide activity: analysis of growth hormone-releasing hormone, thyroid hormone-releasing hormone, and gonadotropin-releasing hormone.
    Bercu BB; Yang SW; Masuda R; Walker RF
    Endocrinology; 1992 May; 130(5):2579-86. PubMed ID: 1315249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
    Van den Berghe G; de Zegher F; Baxter RC; Veldhuis JD; Wouters P; Schetz M; Verwaest C; Van der Vorst E; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1998 Feb; 83(2):309-19. PubMed ID: 9467533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
    Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.